PCRX NASDAQ Week ended 31 Jul 2026

Weekly Investor Report

Pacira BioSciences, Inc. · Healthcare · Drug Manufacturers - Specialty & Generic

Open interactive chart View report data
Latest close 26.41 USD
2.0% latest week
Weekly setup

Constructive, but selective

The weekly trend is active. Price is 13.7% above the Trend Line and sits at 86.1% of its 52-week range. The latest completed week returned 2.0%, after a 4.0% four-week move. The latest factor snapshot indicates quality is middle-of-the-pack; growth ranks weakly; valuation is neither clearly cheap nor expensive. Options positioning is bullish with 41/100 conviction, while the latest news-sentiment score is 55/100. Near-term considerations: earnings are due in 2d.

Setup score 56 out of 100
Latest Close 26.41 USD 31 Jul 2026
1W Return 2.0% latest completed week
4W Return 4.0% short-term follow-through
12W Return 14.1% quarterly tape
Trend Breadth 23.1% 12 of 52 weeks active
Volume Ratio 1.1x vs 13-week average
What is working
  • The trend backdrop is active with a 5-week active streak.
  • Price is above the Trend Line, keeping the weekly tape constructive.
  • Price is above Fair Value, showing premium demand versus the model.
  • Activity pressure is positive on the latest completed week.
What could go wrong
  • Next-week expectancy is negative at 43.92% based on similar historical setup states.
What to watch next
  • Price is close to its 52-week high; watch for continuation or exhaustion.
  • Trend Line remains the key weekly regime level.
  • Activity pressure is the gauge to monitor for confirmation or fade.
  • A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through 2.0% Latest completed week; four-week move 4.0%. Indicator stack 30/95 Trend and activity pressure are weighted against the latest 12-week confirmation window. Trend backdrop Active The trend backdrop defines the current weekly regime. Patient Capital Quiet Activity-pressure buy-signal status for institutional accumulation timing. Next-Week Expectancy Negative 43.92% Historical one-week expectancy contributes to the evidence score when direction is confirmed. Options pressure Bullish 41/100 conviction; expected move 12.6%. News sentiment 55/100 47 relevant articles in the latest sentiment read. Event risk 2d Next report is scheduled for 04 Aug 2026; event risk rises as the date approaches.
01 · Price action

Where price is—and whether the trend supports it

The weekly trend is active. Price is 13.7% above the Trend Line and sits at 86.1% of its 52-week range. The latest completed week returned 2.0%, after a 4.0% four-week move.

Study the full chart

52-week price path

Price vs Trend Line and Fair Value
Price Trend Line Fair Value
02 · Volume and demand

Is real participation confirming the move?

Latest weekly volume is 1.1x the 13-week average. Participation is around or above normal and provides reasonable confirmation.

26-week volume confirmation

Bar height shows volume; colour shows the weekly price direction
6 Feb 13 Feb 20 Feb 27 Feb 6 Mar 13 Mar 20 Mar 27 Mar 3 Apr 10 Apr 17 Apr 24 Apr 1 May 8 May 15 May 22 May 29 May 5 Jun 12 Jun 19 Jun 26 Jun 3 Jul 10 Jul 17 Jul 24 Jul 31 Jul
Up week Down week
Demand beneath price

Activity pressure and institutional-style signals

These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.

Activity pressure path

Latest 0.4812-week average 0.40

12-week confirmation

Trend active5/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure10/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership1/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.48Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers

No recent accumulation markers. No reversal markers.

03 · Momentum and leadership

Is performance persistent—and is the stock leading?

Performance is 4.0% over four weeks, 14.1% over 12 weeks, and 19.7% over one year. The current trend has remained active for 5 consecutive weeks.

Performance by holding period

1W2.0%
4W4.0%
12W14.1%
26W28.6%
52W19.7%
Active trend streak5 weeks
Active weeks in one year12
Trend breadth23.1%

Activity pressure vs relative leadership

Activity pressureRelative leadership
Pressure1.02Latest activity-pressure read.
Pressure change327.3%Four-week change in activity pressure.
Leadership1.27Latest relative-leadership reading.
RS change119.4%Four-week change in relative leadership.
04 · Fundamentals and valuation

What investors are paying for—and the quality behind it

The latest factor snapshot indicates quality is middle-of-the-pack; growth ranks weakly; valuation is neither clearly cheap nor expensive.

Open full factor analysis
Factor week 26 Jul 2026 Financial statements through 31 Mar 2026 Field coverage 94% Model confidence 90%

Relative factor standing

Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.

Overall factor strength37/100Blend of value, momentum, and quality. Underlying universe rank 64; rank 1 is best.
Value30/100Relative valuation strength. Underlying universe rank 71; rank 1 is best.
Quality80/100Profitability and accounting quality. Underlying universe rank 21; rank 1 is best.
Momentum35/100Medium-term price momentum. Underlying universe rank 66; rank 1 is best.
Growth8/100Revenue and earnings growth. Underlying universe rank 93; rank 1 is best.
How to read this

Quality and valuation are separate questions

A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.

Value-quality framework7/100Value and quality alignment from the Sharemaestro SVQF framework.

Valuation

How much investors are paying for earnings, sales, and cash flow.

P/E
198.2x
Price divided by trailing earnings.
Price / sales
1.4x
Market value relative to trailing revenue.
EV / EBITDA
10.9x
Enterprise value relative to operating cash earnings.
Free-cash-flow yield
11.8%
Free cash flow as a share of enterprise value.

Business quality

Margins and the return generated on invested capital.

Gross margin
79.3%
Gross profit retained from each unit of revenue.
Operating margin
3.7%
Operating profit retained from revenue.
Free-cash-flow margin
20.6%
Free cash flow generated from revenue.
Return on invested capital
1.2%
Operating return generated on invested capital.

Growth and financial strength

Recent business growth and accounting strength.

Revenue growth
4.6%
Latest one-year revenue growth.
EPS growth
-
Latest one-year earnings-per-share growth.
Free-cash-flow growth
-21.0%
Latest one-year free-cash-flow growth.
Piotroski F-score
8/9
Nine-point accounting-strength checklist.

Shareholder return and balance sheet

Cash returned to owners and financial leverage.

Dividend yield
-
Cash dividends relative to market value.
Buyback yield
19.2%
Net share repurchases relative to market value.
Shareholder yield
19.2%
Dividend yield plus net buyback yield.
Net debt / EBITDA
2.3x
Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment

What other market participants are doing

Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.

Options positioningBullish

PCRX shows bullish options pressure with a 41/100 conviction score, put-call volume ratio of 0.50, expected move of 12.6%, and Sharemaestro trend signal active.

Conviction41/100
Expected move12.6%
Put/call volume0.50
Pressure41
Speculation8
Volatility77
Trend agreement53
Open options detail
Insider activity15 / 5

15 acquisitions and 5 disposals in the latest 180-day insider tape.

Acquisitions / disposals over the latest 180 days. Insider activity is context, not a stand-alone signal.
News sentiment55/100

Weighted news tone is neutral across 47 relevant articles.

14 positive · 31 neutral · 2 negative
Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal
06 · Catalysts and risk

What can move the shares—and how volatile the path has been

Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.

Next earnings2dNext report is scheduled for 04 Aug 2026; event risk rises as the date approaches.
Options expected move12.6%Nearest-chain priced movement where available.
52-week drawdown-4.5%Distance below the 52-week high.
13-week volatility4.2%Standard deviation of weekly returns.

Weekly gains and losses

Latest 26 completed weeks

Each bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.

Weeks higher16 of 2610 weeks finished lower.
Best week+13.0%Week of 26 Jun.
Worst week-5.6%Week of 27 Feb.
Latest week+2.0%Week of 31 Jul.

Shape of recent returns

Strong gains4
Modest gains12
Flat weeks0
Modest losses7
Sharp losses3
Recent vol4.2%13-week weekly-return volatility.
Base vol5.4%52-week weekly-return volatility.
Up/down split29/23Count of positive and negative weeks in the 52-week window.
Average skew3.9% / -3.8%Average positive week versus average negative week.
07 · Sector and peer context

Is this stock leading—or simply moving with its group?

Sector and industry breadth distinguish company-specific strength from a broad group move.

08 · Evidence and weekly data

The underlying research record

Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.

Weekly tape53/100

Trend, activity pressure, participation, and risk combine to a 53/100 tape read.

 Indicator analysis47/100

Latest 12-week confirmation: trend 5/12, activity pressure 10/12, relative leadership 1/12.

Activity pressure 0.48; No reversal markers Next-Week ExpectancyNegative 43.92%

Next-week expectancy is negative with a 43.92% historical one-week setup read.

Adds short-term historical context without overriding trend, activity, or relative leadership. Factors45/100

O'Shaughnessy factor stack blends value, quality, momentum, and confidence.

Buyback Yield rank 3; Small Cap Core rank 27 SVQF7/100

Value and quality alignment from the Sharemaestro SVQF framework.

Composite rank 673.0 of 726 Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal Options57/100

PCRX shows bullish options pressure with a 41/100 conviction score, put-call volume ratio of 0.50, expected move of 12.6%, and Sharemaestro trend signal active.

Bullish · Call-side pressure · Expected move 12.6% Sentiment55/100

Weighted news tone is neutral across 47 relevant articles.

Will Pacira’s (PCRX) U.S. Manufacturing Shift for PCRX-201 Redefine Its Post-EXPAREL Narrative? Insiders15 / 5

15 acquisitions and 5 disposals in the latest 180-day insider tape.

 Earnings2d

Next report is scheduled for 04 Aug 2026; event risk rises as the date approaches.
WeekCloseReturnTrend LineFair ValuePressureLeadershipVolumeTrend
31 Jul 202626.41 USD2.0%23.22 USD24.71 USD1.021.272.7MOn
24 Jul 202625.88 USD1.1%23.16 USD24.79 USD0.90-0.302.7MOn
17 Jul 202625.61 USD0.5%23.18 USD24.86 USD0.90-3.022.7MOn
10 Jul 202625.48 USD0.4%23.20 USD24.93 USD0.51-7.612.1MOn
3 Jul 202625.39 USD0.6%23.23 USD25.01 USD0.24-6.571.9MOn
26 Jun 202625.24 USD13.0%23.18 USD25.09 USD0.01-6.613.0MOff
19 Jun 202622.33 USD-2.9%23.13 USD25.18 USD-0.26-21.382.2MOff
12 Jun 202622.99 USD1.1%23.15 USD25.29 USD-0.07-17.561.8MOff
5 Jun 202622.75 USD-2.0%23.18 USD25.41 USD0.02-17.132.0MOff
29 May 202623.22 USD-0.6%23.15 USD25.50 USD0.20-19.891.7MOff
22 May 202623.35 USD3.1%23.09 USD25.60 USD0.52-17.862.6MOff
15 May 202622.64 USD-2.2%23.04 USD25.70 USD0.70-20.092.8MOff
8 May 202623.15 USD-5.3%23.05 USD25.82 USD0.87-19.253.1MOff
1 May 202624.44 USD-0.3%23.02 USD25.94 USD0.84-10.884.2MOff
How to use this report

This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.